Business / Finance

RSS

Inhibitex third quarter revenue increases to $1.3 million

Inhibitex, Inc. today announced its financial results for the third quarter ended September 30, 2011 and provided an update on several recent corporate developments, including top-line safety and antiviral data from the first cohort in its ongoing clinical trial designed to evaluate higher doses of INX-189, an oral nucleotide polymerase inhibitor, being developed to treat chronic infections caused by hepatitis C virus (HCV), administered as monotherapy or in combination with ribavirin for seven days.

4 Nov 2011

Vanda third quarter total revenues increase to $8.0 million

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the third quarter and nine months ended September 30, 2011.

4 Nov 2011

Savient third quarter net loss decreases to $27.4 million

Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.

3 Nov 2011

POZEN third quarter revenue increases to $4.9 million

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the third quarter ended September 30, 2011.

3 Nov 2011

Zynex third quarter net revenues increase 42% to $9,427,000

Zynex, Inc., a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announces its third quarter 2011 financial results.

3 Nov 2011

Columbia Laboratories third quarter total net revenues decrease to $4.9 million

Columbia Laboratories, Inc. today reported financial results for the three- and nine-month periods ended September 30, 2011.

3 Nov 2011

Allos third quarter net loss decreases to $11.2 million

Allos Therapeutics, Inc. today reported financial results for the three months ended September 30, 2011.

3 Nov 2011

ARIAD reports net income of $13.9 million for third quarter 2011

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter of 2011 and provided an update on its corporate developments.

3 Nov 2011

Abiomed second quarter revenue increases 26% to $29.5 million

Abiomed, Inc., a leading provider of breakthrough heart support technologies, today reported second quarter fiscal 2012 revenue of $29.5 million, up 26% compared to revenue of $23.4 million in the same period of fiscal 2011.

3 Nov 2011

SXC third quarter revenue increases 163% to $1.3 billion

SXC Health Solutions Corp., a leading provider of technology and pharmacy benefit management (PBM) services, announces its financial results for the three-month and nine-month periods ended September 30, 2011.

3 Nov 2011

CPM enters definitive merger agreement with HealthGrades

HealthGrades, the leading provider of information to help consumers make an informed decision about a physician or hospital and CPM, the leading provider of customer relationship management solutions for hospitals today announced a definitive agreement to merge the two companies.

3 Nov 2011

Reliv third quarter net sales decrease 7.3% to $17.3 million

Reliv International, Inc., a maker of nutritional supplements that promote optimal health, today reported its financial results for the third quarter of 2011.

2 Nov 2011

Celldex third quarter net loss increases to $11.8 million

Celldex Therapeutics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2011. Celldex reported a net loss of $11.8 million, or $0.27 per share, for the third quarter of 2011 compared to a net loss of $9.1 million, or $0.28 per share, for the third quarter of 2010.

2 Nov 2011

AVEO third quarter net loss increases to $23.8 million

AVEO Pharmaceuticals, Inc. today reported consolidated financial results for the third quarter of 2011 and provided an update on the tivozanib clinical program.

2 Nov 2011

DJO Global third quarter net sales increase 12.7% to $263.1 million

DJO Global, Inc., a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its operating subsidiary, DJO Finance LLC, for the third quarter of fiscal 2011, ended October 1, 2011.

2 Nov 2011

Zalicus third quarter revenue increases to $2.4 million

Zalicus Inc. today reported financial results for the third quarter ended September 30, 2011.

2 Nov 2011

Teva third quarter net sales increase 2% to $4.34 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended September 30, 2011.

2 Nov 2011

SurModics to sell Pharma assets to Evonik for $30 million

SurModics, Inc., a leading provider of surface modification technologies to the healthcare industry, announced today that it has entered into a definitive agreement to sell its SurModics Pharmaceuticals assets to Evonik Industries AG for $30 million in cash.

2 Nov 2011

MEDNAX acquires Bexar Pediatric Surgery in San Antonio

MEDNAX, Inc., today announced the acquisition of a pediatric surgery physician group practice based in San Antonio, TX.

1 Nov 2011

MEDNAX third quarter net income increases 15.7% to $58.2 million

MEDNAX, Inc., the national medical group specializing in neonatal, maternal-fetal, pediatric cardiology, other pediatric subspecialties and anesthesia physician services, today reported earnings per share of $1.19 for the three months ended September 30, 2011.

1 Nov 2011